What evaluation and management are recommended for a self‑referred patient who developed tachycardia after an eye‑doctor visit, possibly due to ocular dilating drops?

Evaluation and Management of Tachycardia After Eye Clinic Visit

This patient most likely experienced a sympathomimetic reaction from phenylephrine dilating drops, and your immediate priority is to obtain a focused history about the timing, duration, and current status of symptoms, perform an ECG, and check vital signs to rule out ongoing arrhythmia or hypertensive crisis.

Initial Assessment

The clinical scenario strongly suggests drug-induced tachycardia from ophthalmic phenylephrine (2.5% or 10%), which can cause significant systemic absorption and cardiovascular effects 1, 2. Your evaluation should focus on:

Key History Elements

• Exact timing: When did symptoms start relative to drop instillation? (Typically within minutes to 30 minutes)
• Current symptoms: Is the patient still tachycardic, hypertensive, or symptomatic now?
• Drop type used: Phenylephrine is the primary culprit; tropicamide rarely causes cardiovascular effects
• Symptom characteristics: Palpitations, chest pain, confusion, headache, or syncope
• Cardiac history: Any prior arrhythmias, structural heart disease, or coronary disease

Immediate Workup

• 12-lead ECG: Essential to identify the specific arrhythmia (sinus tachycardia vs. SVT vs. other) and rule out ischemic changes 2
• Vital signs: Blood pressure (phenylephrine commonly causes hypertension 1, 2), heart rate, oxygen saturation
• Cardiac biomarkers: If chest pain, ECG changes, or prolonged symptoms—phenylephrine can cause troponin elevation 2

Clinical Decision-Making

If Currently Symptomatic with Ongoing Tachycardia

For hemodynamically stable patients with suspected SVT (AVNRT most common):

1. First-line: Vagal maneuvers 3

   • Valsalva maneuver (bearing down 10-30 seconds, ≥30-40 mmHg pressure) in supine position
   • Carotid massage (after confirming no bruit) for 5-10 seconds
   • Ice-cold wet towel to face
   • Success rate ~28% when switching between techniques

2. Second-line: IV adenosine (Class I recommendation) 3

   • Terminates AVNRT in ~95% of cases
   • Also diagnostic—will unmask atrial activity if atrial flutter or AT

3. Third-line: IV beta-blockers, diltiazem, or verapamil (Class IIa) 3

4. If hemodynamically unstable: Synchronized cardioversion (Class I) 3

For sinus tachycardia from phenylephrine:

• Supportive care—effects are self-limited (typically resolve within 1-2 hours)
• Treat hypertension if severe (>180/120 mmHg) with short-acting agents
• Beta-blockers can be considered if symptomatic and no contraindications

If Currently Asymptomatic (Symptoms Resolved)

The patient likely experienced transient sinus tachycardia or brief SVT that self-terminated. However, you must still:

• Obtain ECG: Look for baseline conduction abnormalities, pre-excitation (WPW), or other substrate for arrhythmia
• Document the episode: Rhythm, duration, associated symptoms
• Risk stratify for recurrence: If this was true SVT (not just sinus tachycardia), consider cardiology referral

Critical Pitfalls to Avoid

1. Don't assume benign sinus tachycardia without ECG confirmation—phenylephrine can unmask underlying arrhythmia substrates 1

2. Don't miss conduction disease in elderly patients—mydriatic drops have triggered trifascicular block with syncope 4 and AV blocks 5

3. Don't overlook coronary vasospasm—phenylephrine can precipitate vasospastic angina, especially in patients on beta-blockers 6

4. Don't forget to check if patient is on ophthalmic beta-blockers (timolol, carteolol)—these can cause bradycardia and AV blocks 5 and worsen vasospastic angina 6

Disposition and Follow-up

• Admit if: Ongoing symptoms, hemodynamic instability, ECG abnormalities, elevated troponin, or high-risk features
• Discharge if: Completely asymptomatic, normal ECG, normal vital signs, and reliable for follow-up
• Outpatient cardiology referral: If documented SVT episode (not just sinus tachycardia) for consideration of electrophysiology study and possible ablation
• Patient education: Inform about phenylephrine sensitivity; document allergy/adverse reaction in chart for future eye procedures

The vast majority of these cases represent self-limited sympathomimetic effects that resolve spontaneously within 1-2 hours 7, but your evaluation must exclude the rare but serious complications documented in case reports 1, 2, 4.